Floatz logo

FULVESTRANT

Low Grade Serous Carcinoma

Gynecologic Oncology GroupSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Low Grade Serous Carcinoma cohort.

Asset / SponsorPhaseRating
Letrozole
Gynecologic Oncology Group
Phase 2/3BB
Epirubicin
North Eastern German Society of Gynaecological Oncology
Phase 2CCC
Pembrolizumab
North Eastern German Society of Gynaecological Oncology
Phase 2CCC
Cyclophosphamide
North Eastern German Society of Gynaecological Oncology
Phase 2CCC
LEUPROLIDE
Gynecologic Oncology Group
Phase 2CCC
Ribociclib
Gynecologic Oncology Group
Phase 2CCC
Zoladex
Gynecologic Oncology Group
Phase 2CCC

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant
BB
Indicative ·
70 / 100
View asset →
hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Progesterone Receptor PositiveDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →